Skip to content
  • French
  • English
  • Dutch
  • German
Delbert Pharma Logo Delbert Pharma Logo Delbert Pharma Logo
  • The Laboratory
  • Our Vision
  • Expertise
  • Products
  • Partners
  • News
  • Contact

Acquisition of TERALITHE® by the Laboratoires Delbert

Acquisition of TERALITHE® by the Laboratoires Delbert
Communique de presse - teralithe april 22final
edv2022-05-18T13:36:06+00:00May 17th, 2022|

Actualités / News

  • Availability of XYLLOMAC® 1g, powder for solution for injection/IM-IV infusion, box of 1, in pharmacies 13/12/2023
  • Commercialisation of LORAZEPAM XILMAC® 4mg/ml, solution for injection, in France 06/11/2023
  • Availability of Ceplene® 0.5mg/0.5ml, solution for injection (Histamine dihydrochloride), in Germany and Austria 09/10/2023
  • Availability of Prostaphlin® 1000 mg for Czech market 26/01/2023
  • Commercialization of amoxicilline in Ireland 16/01/2023
  • THE LABORATOIRES DELBERT ANNOUNCES A SERVICES AGREEMENT WITH IBI 30/11/2022
  • Acquisition de TERALITHE® par les Laboratoires Delbert 05/07/2022
  • Acquisition of TERALITHE® by the Laboratoires Delbert 17/05/2022
  • Laboratoires Delbert – Help to Ukraine 14/04/2022
  • Augmentin® injectable devient Levmentin® : informations et dates de mise à disposition 07/03/2022
Logo Laboratoires Delbert

49, rue Rouelle
75015 Paris
France
Phone + 33 1 46 99 68 20

Download the company information sheet of Delbert Pharma

  • Terms & Conditions
  • Privacy Policy
  • Contact
All rights reserved to the Laboratoires Delbert© . RCS Paris 443 960 570 - SAS with capital of 217 928 €
Page load link
  • French
  • English
  • Dutch
  • German
By continuing to browse, you accept the use of third-party services that may install cookiesOKNoprivacy policy
Go to Top